Table 2.

In vitro antifungal activity of AmB nanoformulations against commercial products and plain AmB (n = 3 minimum). IC_50s of nanoformulations are expressed as equivalent concentration of AmB.

AmB nanoformulation and model drug	In vitro activity, IC50  ±  SD (μg/mL) on
	A.  fumigatus		A.  niger		A.  flavus		C.  albicans
	24 h	48 h	24 h	48 h	24 h	48 h	24 h	48 h
AmB	1.44 ± 0.11	1.38 ± 0.01	1.68 ± 0.01	1.63 ± 0.07	1.33 ± 0.11	1.27 ± 0.33	0.59 ± 0.03	0.55 ± 0.08
Fungizone	0.49 ± 0.31	0.41 ± 0.02	0.57 ± 0.03	0.53 ± 0.01	0.41 ± 0.02∗∗∗	0.39 ± 0.14	0.29 ± 0.021	0.26 ± 0.013
AmBisome	1.92 ± 1.03	1.84 ± 0.02∗∗∗	2.01 ± 1.23	1.93 ± 0.02	1.69 ± 0.33∗∗∗	1.56 ± 0.02∗∗∗	0.52 ± 0.41	0.50 ± 1.14
CS-AMB-NP	0.50 ± 0.01	0.45 ± 0.03	0.74 ± 011	0.68 ± 0.03	1.56 ± 0.02	1.51 ± 1.11	0.26 ± 1.23	0.21 ± 0.01
CS-AMB-POR	0.10 ± 0.01	<0.08∗∗∗	0.17 ± 0.01	0.16 ± 0.02	0.12 ± 0.02	0.10 ± 0.03∗	0.08 ± 0.03∗∗∗	<0.04∗∗
CS-AMB-POR-TPP	0.16 ± 0.02	0.15 ± 1.11	0.11 ± 0.01	0.10 ± 1.37	0.11 ± 0.02	0.09 ± 0.01	0.08 ± 0.02∗∗∗	<0.03∗∗∗

n = 6 in each group. Values are expressed as mean ± S.E.M. Data was analyzed by one-way ANOVA followed by Tukey's post hoc test.

^∗Significant difference with AmB, pb0.05.

^∗∗Significant difference with AmB, pb0.01.

^∗∗∗Significant difference with AmB, P ≤ 0.001.